Tag Archives: TOMI Environmental Solutions

Peer Reviewed Paper Concluded The Use of TOMI’s SteraMist™ BIT™ Contributed To the Substantial Reduction In a Wilmington, Delaware Hospital’s Clostridium difficile (C. diff.) Burden

TOMI Environmental Solutions, Inc. (“TOMI”)  a global decontamination and infection prevention company that specializes in disinfection/decontamination sales and services, including the manufacturing, sale and licensing of its SteraMist™, a hydrogen peroxide-based mist/fog that is registered with the U.S. Environmental Protection Agency (“EPA”), announced the publication of a peer reviewed paper titled “Use of Novel Approaches to Reduce Clostridium Difficile in an Inner City Hospital,” which concluded that the use of TOMI’s SteraMist™ BIT™ contributed to the substantial reduction in a Wilmington, Delaware hospital’s Clostridium Difficile (C. Diff) burden. The paper was written by Dr. Helene Paxton, MS, MT (ASCP), PhD, CIC, Infection Preventionist, Bio Guidance, LLC and member of TOMI’s Science Advisory Board, and outlines the incorporation of SteraMist™ BIT™ into everyday disinfection protocols of a healthcare facility. This paper was peer reviewed by Dr. Uyen Nguyen.

“In the healthcare space, TOMI has been making strides to continuously demonstrate the efficacy of SteraMist™ in combating and reducing hospital infections,” said Dr. Halden Shane, CEO and Chairman of TOMI Environmental Solutions, Inc. “This further review and publication of the efficacy of TOMI’s SteraMist™ is an important verification in our battle to address the increase in C. diff infections, which lead to thousands of deaths in the U.S. each year.”

To read this article in its entirety please click on the following link:

https://globenewswire.com/news-release/2017/04/03/953811/0/en/SteraMist-Contributes-to-Substantial-Reduction-in-Clostridium-Difficile-Burden-in-Hospital.html

Nearly 300 people die in the U.S. every day from an infection they acquired during their hospital stay, and the death toll is even higher internationally. Healthcare Associated Infections (HAIs), including Methicillin-resistant Staphylococcus aureus (MRSA), are becoming an international crisis. Bacterial spores such as C. diff have become an even larger problem in hospitals and in their respective communities, and it is estimated that nearly half a million Americans contract C. diff every year.

TOMI’s EPA registered BIT™ (Binary Ionization Technology®), branded as SteraMist™, converts a low percentage hydrogen peroxide into a hydroxyl radical by passing the liquid through an atmospheric cold plasma arc, a technology initially developed under the sponsorship of the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. SteraMist™ BIT™ quickly destroys deadly viruses, bacteria and spores before they pose a threat to patients, healthcare workers and their communities.

TOMI’s SteraMist™ helps hospitals reduce their HAI rates by destroying the microscopic germs that may be missed during the manual cleaning process. TOMI’s germ fighting technology uses an environmentally-friendly process, the only by-product of which is oxygen and humidity. The SteraMist™ aerosol quickly destroys infectious germs in less than five seconds. Hospitals using SteraMist™ devices have reported and published outcomes in papers and in a peer-reviewed journal showing significant decreases in C. diff rooms after the use of SteraMist.

Dr. Shane further stated: “Hospitals can and should do more to keep patients safe. No one wants a loved one to go to the hospital and contract C. diff or any hospital acquired infection. Hospitals routinely using SteraMist™ have repeatedly demonstrated lower infection rates, which leads to enhanced patient and employee safety. Hospitals using our technology can stop the spread of infections while improving their bottom line.”

Uniquely designed for ease of use and portability, a hospital’s environmental services staff can operate SteraMist™ quickly without disrupting hospital operations. With a five second exposure time, the surface unit can disinfect a hospital room’s high touch surfaces and delicate medical equipment in less than 10 minutes. SteraMist™ is designed to go in, above, beyond, under and around objects in patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas. SteraMist™ does not damage medical equipment. Many hospitals in the U.S., Europe, West Africa, Central America and Asia have used SteraMist™ in their decontamination protocols. SteraMist™is also used in skilled nursing facilities, ambulatory surgery centers, long term acute care facilities and childcare facilities.

About TOMI Environmental Solutions, Inc.

TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing eco-friendly environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion) and is represented by the TOMI™ SteraMist™ brand of products, which produce a germ-killing aerosol that behaves like a gas.

TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association. For additional information, visit www.tomimist.com or contact us at info@tomimist.com.

Cautionary Statement Regarding Forward Looking Statements

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

DISCLAIMER
“The C Diff Foundation’s mission is to educate and advocate for Clostridium difficile infection prevention, treatments, support, and environmental safety worldwide.
 
The C Diff Foundation’s organization is comprised of 100% volunteering members who are dedicated to our mission and adhere to the Foundation’s Code of Ethics
which prohibits the endorsement and promotion of products, services, medications, or clinical studies in progress. 
 
All website entries, public presentations, and workshops are to raise C. diff. infection awareness in all areas of the C Diff Foundation’s mission statement, including infection prevention, sepsis, healthcare-associated infections, antimicrobial resistance, antibiotic stewardship and provide education on all the above.”

TOMI Environmental Solutions and C. diff. An Ever Increasing Problem For a Healthcare Facility By: Dr. Helene Paxton

Shared by TOMI Environmental Solutions

C.DIFF AN EVER INCREASING PROBLEM FOR A HEALTHCARE FACILITY
By: Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC, Infection Preventionist, Bio Guidance, LLC.

http://tomimist.com/white-paper-c-diff-an-ever-increasing-problem-for-a-healthcare-facility/

 

MORE about TOMI™ Enviornmental Solutions, Inc.

Feb. 23, 2016 (GLOBE NEWSWIRE) — TOMI™ Environmental Solutions, Inc.  a global bacteria decontamination and infection prevention company, announced the United States Environmental Protection Agency (EPA) has amended TOMI’s registration for its patented Binary Ionization Technology (BIT™) to include its effectiveness in disinfecting Clostridium difficile spores (C. diff)+, Methicillin Resistant Staphylococcus aureus (MRSA)**and influenza (H1N1)**.

 TOMI™ Expands Opportunity in US Hospital and Healthcare Markets With Amended EPA Registration

SteraMist™ BIT™ Efficacy data

 

TOMIEnvironmental Solutions, Inc. is a leading provider of infection prevention and decontamination products and services, focused primarily on life sciences including healthcare, bio-safety, pharmaceutical, clean-room and research. Our mission is to help our customers create a healthier world through TOMI’s product line. TOMI’s motto is “Innovating for a Safer World” for healthcare and life.

As a global decontamination and infectious disease control company, TOMI provides environmental solutions for indoor and outdoor surface decontamination through the sale of equipment, services and licensing of our SteraMist™ Binary Ionization Technology® (BIT™) which is a EPA registered hydrogen peroxide based mist and fog.

During August 2010, TOMI entered into negotiations to purchase the assets of a U.S. Defense company’s division that owned and operated BIT. The technology was a division of L-3 Applied Technologies, Inc. (L-3). In April 2013, we completed the acquisition of certain assets from L-3 for $3,510,000 and TOMI began to develop, engineer and complete regulatory testing for the EPA registrations of BIT and BIT Solution as a Hospital-Healthcare Disinfectant.  BIT  is the platform that runs our SteraMist equipment that currently accounts for nearly all of our revenue.

TOMI re-engineered the prototypes into TOMI’s current model of Binary Ionization Technology® (BIT™), branded as SteraMist™. This technology was developed for the neutralization of anthrax spores and sponsored by the U.S. Defense Advanced Research Projects Agency (DARPA).  This novel DARPA project was sanctioned under DARPA/CMO Contract No. MDA972-03-C-0092 and developed through the Special Projects Office/SPO.: Immune Building
DARPA Order No. P896/00 Program Code: 3310 3701 North Fairfax Drive
Arlington, VA 22203-1714.

In June 2015, SteraMist™ BIT™ was granted a registration from the US Environmental Protection Agency (EPA) as a hospital-healthcare disinfectant for use as a misting/fogging agent (EPA Registration 90150-2). Our product also holds a second EPA registration for mold control and air & surface remediation (EPA Registration 90150-1).

SteraMist™ Binary Ionization Technology® (BIT™)

BIT™ was developed in response to Amerithrax, the anthrax attacks that occurred in Washington, D.C. shortly after the September 11,2001 US terrorist attacks.  It is a patented two-step process that aerosolizes and activates a low concentration hydrogen peroxide solution producing a fine aqueous mist that contains a high concentration of Reactive Oxidative Species (ROS), mostly hydroxyl radicals. ROS cause damage to pathogenic organisms via mechanisms such as oxidation of unsaturated fatty acids such as carbohydrates, lipids, and amino acids leading to cellular disruption and/or dysfunction. The unique alteration of the chemistry of our solution occurs after passing our EPA registered BIT™ Solution through our atmospheric high voltage cold plasma arc which causes the breaking of the double bond of a hydrogen peroxide molecule.  The net result is the hydroxyl radical. This hydroxyl radical is known as Activated Ionized Hydrogen Peroxide (AIHP). The TOMI™ patented process allows these ROS (hydroxyl radicals) to exist in high concentrations without rapidly recombining and losing their reactivity.

Testing detailed by DARPA demonstrates these ROS, which include the hydroxyl ion and hydroxyl radicals, aggressively break the double bonds in bacterial spores, biological and Chemical warfare agents (BWA and CWA) neutralizing their threat and producing non-toxic by-products.

Brought to the commercial market by TOMI™ in June 2013, our current suite of products includes the SteraMist™ Surface Unit, the SteraMist™ Environment System, and BIT™ Solution. Our SteraMist™ BIT™ platform has expanded beyond the initial chemical and biological warfare applications to deactivate problem microorganisms (including spores) in healthcare, laboratory, clean rooms, and a wide variety of other commercial and residential settings. SteraMist™ BIT™ provides fast acting biological deactivation and works in even the most hard-to-reach areas while leaving no residue or noxious fumes. The by-products produced by SteraMist™ BIT™ are oxygen and humidity.

The SteraMist™ Surface Unit is a fully portable fast-acting, hand held, point and spray disinfection/decontamination system. It is a safe and easy process to make certain that your facility, home, and assets are disinfected/decontaminated to the maximum extent possible. The single applicator Surface Unit enables disinfection of all surfaces–including high touch, sensitive medical equipment, and electronics. The space is safe to re-enter within minutes after the Activated Ionized Hydrogen Peroxide (AIHP) mist has been applied. The EPA registered 5-second application time AND 7-minute contact time seamlessly results in quick room turnover while eliminating pathogens such as MRSA and H1N1.

TOMI’s SteraMist™ Surface Unit is lightweight, easy to transport, and capable of achieving reliable disinfection/decontamination as it is easily incorporated into current cleaning procedures and protocols. The hydroxyl radicals produced by TOMI’s plasma science does not require heating, ventilation, or air conditioning systems to be shut down and requires no wiping, leaves no residue and is a bleach, chlorine, formaldehyde, glutaraldehyde, titanium dioxide, peracetic and silver ion free formula.

The SteraMist™ Environment System is a transportable remotely controlled system that provides complete room disinfection/decontamination of a sealed space, up to 103.8 m3 (3,663 ft3). Individually, each remote applicator can be used to treat a space of approximately 34.6 m3 (1,221 ft3). Multiple Environment Systems can be used simultaneously to accommodate larger spaces. Fast application = minimal down time. Mechanical cleaning that makes whole room disinfecting/decontaminating easier. With this automated touch-less application solution you can treat multiple areas simultaneously. Our hybrid technology – applicators can be used in manual and/or fogging modes. Great for frequent daily use, saves time and labor.  SteraMist™ is a powerful technology in fighting, reducing and eliminating bacteria including C. diff spores and when you reenter the room you can “smell the clean”

TOMI™ currently targets domestic and international markets. Our approach to the international markets is through strategic partners, manufacturer representatives,/or and licensed distribution partners. The company is currently focused in Mexico and Central America, the EU, and Asia where the technology is used for the control of microorganisms and the decontamination of large and small indoor space for biological pathogens and chemical agents. Domestically, TOMI’s primary market is Healthcare-Hospitals, Biosafety, and Pharmaceutical along with many other verticals that TOMI sells to end-users or end-user can elect to have the areas treated through the TOMI Service Network (TSN), a network professional service providers. These include infectious diseases in hospitals, bio-secure labs, pharmaceutical, biodefense, and biosafety facilities – including isolation and transfer chambers, tissue banks, food safety, and many other commercial and residential settings.

TOMI™ has extensive experience in developing training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association.

Source: 

http://tomimist.com/about-us/

 

  • Note:  The C Diff Foundation does not endorse this or any product.  Information posted is to provide information to the general public and for no additional reasons or involvement between parties mentioned.  For information regarding any product, contact the manufacturer, and /or company providing the product and service.  Thank you.